Calpastatin is associated with lymphovascular invasion in breast cancer

Breast. 2011 Oct;20(5):413-8. doi: 10.1016/j.breast.2011.04.002. Epub 2011 May 4.

Abstract

Metastasis of breast cancer is a major contributor to mortality. Histological assessment of vascular invasion (VI) provides important prognostic information and demonstrates that VI occurs predominantly via lymphatics in breast cancer. We sought to examine genes and proteins involved in lymphovascular invasion (LVI) to understand the mechanisms of this key disease process. A gene expression array of 91 breast cancer patients was analysed by an Artificial Neural Network (ANN) approach using LVI to supervise the analysis. 89 transcripts were significantly associated (p<0.001) with the presence of LVI. Calpastatin, a specific calpain inhibitor, had the second lowest selection error and was investigated in breast cancer specimens using real-time PCR (n=56) and immunohistochemistry (n=53). Both calpastatin mRNA and protein levels were significantly associated with the presence of LVI (p=0.014 and p=0.025 respectively). The data supports the hypothesis that calpastatin may play a role in regulating the initial metastatic dissemination of breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Calcium-Binding Proteins / genetics*
  • Calcium-Binding Proteins / metabolism
  • Calpain / antagonists & inhibitors*
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Lymphatic Vessels / metabolism*
  • Middle Aged
  • Neoplasm Invasiveness
  • Predictive Value of Tests
  • Real-Time Polymerase Chain Reaction

Substances

  • Calcium-Binding Proteins
  • calpastatin
  • Calpain